Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma.

Trial Profile

Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2012

At a glance

  • Drugs Imatinib (Primary) ; Panobinostat (Primary)
  • Indications Sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Feb 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 03 Oct 2011 Additional lead trial investigators (Scott Schuetze, Edwin Choy) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top